EGM
GANX icon

Engineers Gate Manager’s Gain Therapeutics GANX Stock Holding History

Engineers Gate Manager’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,617
Closed -$47.1K – 2308
2025
Q4 		$47.1K Buy
+14,617
New +$39K ﹤0.01% 1982

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Engineers Gate Manager's GANX Position: Q1 2026 in Review

Engineers Gate Manager sold out of Gain Therapeutics (GANX) in Q1 2026, closing a stake of 14,617 shares — an estimated $47.1K sold.

Engineers Gate Manager first reported a position in GANX in Q4 2025 and held it in 1 quarter. The position peaked at $47.1K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Engineers Gate Manager reported no remaining Gain Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Engineers Gate Manager sold 14,617 Gain Therapeutics shares in Q1 2026, an estimated $47.1K.
  • Engineers Gate Manager first reported a position in Gain Therapeutics in Q4 2025 and held it in 1 quarter.
  • Engineers Gate Manager's Gain Therapeutics position peaked at $47.1K in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.